|
|
|
|
|
|
Commercial Strategy Development: A small public biotech company previously focused on drug discovery and development sought Health Advances' help
to develop a strategy to build a more fully integrated organization. We helped prepare a comprehensive plan that included a reprioritized product portfolio, a
detailed in-licensing and out-licensing plan, an infrastructure plan, and pro-forma financials to guide our client's transition.
Biotech Transformation Strategy: Working directly with the new CEO, Health Advances led a planning process to lay out a multi-year plan for
transforming the company from a platform company into a product company. The plan would completely change the vision and business model, and required an
extensive examination of how that company might create a product portfolio and assemble the required organizational skills.
Turnaround Strategy: The client team sought a strategy that would dramatically enhance the momentum for the company. By reviewing the
technology platform and portfolio, organizational strengths, and opportunities to apply those in new areas, we identified several new strategic directions
for the company and developed detailed plans for building internal skills capabilities and driving business development activities.
M&A Strategy and Due Diligence: A Cambridge-based biotech company seeking to complete a major acquisition engaged Health Advances to conduct
an extended acquisition-focused project. Over a period of months, and in parallel with due-diligence level review of several possible candidates, Health Advances
advised the management team on the criteria that management should use for evaluating the attractiveness and strategic fit.
Drug Out-Licensing Support: Our client, a small public biotech company, engaged Health Advances to assist with the out-licensing of a protein
therapeutic for use in wound healing. During our analysis we identified a second possible application, prepared a market analysis, and proposed development
steps required to make this new indication a strong component of the licensing package offered to potential partners.
|
|
 |
|
|
|
|
